Esperion Therapeutics, Inc. (NASDAQ: ESPR)

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing oral medicines for patients with cardiovascular disease and elevated low density lipoprotein cholesterol. The company's lead products are NEXLETOL and NEXLIZET which are once daily tablets that do not contain a statin. These medicines are approved in the United States Europe Switzerland and other jurisdictions to lower low density lipoprotein cholesterol and to reduce the risk of major cardiovascular events in patients who cannot or will not take statin therapy. Esperion also advances a preclinical pipeline of next generation ATP citrate lyase inhibitors and pursues business development to expand its portfolio beyond the bempedoic acid franchise.

Esperion generates revenue from two main sources product sales and collaboration revenue. Product sales come from the commercial sale of NEXLETOL and NEXLIZET in the United States. Collaboration revenue consists of milestone payments royalties and sales of bulk tablets to partners outside the United States including Otsuka Pharmaceutical Co Ltd Daiichi Sankyo Europe GmbH and others. In 2025 the company recorded 159.6 million dollars in net product sales and 243.6 million dollars in collaboration revenue.

Esperion occupies a niche in the cardiovascular therapeutics market as the first company to bring an oral non statin ACLY inhibitor to patients. Its products have demonstrated both low density lipoprotein cholesterol reduction and cardiovascular risk reduction in the CLEAR Outcomes trial which showed a 13 percent reduction in major adverse cardiac events. Competitors include large pharmaceutical firms such as Amgen Pfizer and Merck that market injectable PCSK9 inhibitors as well as generic statin manufacturers and other non statins like ezetimibe. Esperion's competitive advantages stem from its novel mechanism of action its oral once daily dosing and the robust clinical evidence supporting its use in statin intolerant patients.

Esperion's customers include health care providers who prescribe its medicines pharmacies that dispense the tablets and patients who suffer from cardiovascular disease or high low density lipoprotein cholesterol and are unable or unwilling to take statin therapy. The company also works with collaboration partners such as Otsuka Pharmaceutical Co Ltd Daiichi Sankyo Europe GmbH Daiichi Sankyo Co Ltd Neopharm CSL Seqirus and HLS Therapeutics Inc which handle regulatory approval marketing and distribution in their respective territories.